Trial reportClinical ophthalmology (Auckland, N.Z.)2025
A Clinical Evaluation of Lifitegrast Ophthalmic Solution 5% in Symptomatic Contact Lens Wearers.
Trial report in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Harnessing exosomes in dry eye disease: a triple threat approach.BMC ophthalmology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the effectiveness of lifitegrast ophthalmic solution 5% in alleviating end-of-day dryness and discomfort in symptomatic contact lens (CL) wearers. Patients and Methods: This was an open-label study in symptomatic CL wearers with ratings of ≥40 for end-of-day dryness on a visual analog scale (VAS; 0-100 scale; 100 worst). Participants wore their habitual CLs and instilled lifitegrast twice daily for 12 weeks with lenses removed. The performance of lifitegrast was assessed by comparing VAS 0-100 ratings (100=worst) at 2, 6 and 12 weeks for end-of-day dryness and discomfort and Contact Lens Dry Eye Questionnaire-8 (CEQ-8) scores to baseline levels. Tear samples were collected at all visits to measure 10 different tear cytokines. Results: Forty participants (33F, mean age 30.8±12.1 years, 65% daily disposable CL users) completed the study. There were no serious adverse events. Median (range) visual analog scale ratings for end-of-day dryness (Baseline: 76 (19-99); 2-weeks: 43 (0-95); 6-weeks: 26 (0-94); 12-weeks: 15 (0-98)) and discomfort (Baseline: 70 (10-97); 2-weeks: 45 (0-95); 6-weeks: 25 (0-84); 12-weeks 11 (0-96)) both significantly improved over time (all p<0.01). At baseline, 100% of participants rated dryness ≥40, which dropped to 17% at 12 weeks. Baseline CLDEQ-8 scores of 22 (12-31) had significantly decreased to 11 (1-26) at 12 weeks. Comfortable CL wear time increased significantly from 6±2 hours at baseline to 9±3 hours at 6 and 12 weeks (all p<0.01). Cytokine levels did not change over time. Conclusion: Lifitegrast significantly improved end-of-day dryness, end-of-day discomfort, CLDEQ-8 scores and comfortable CL wear time within 2 weeks of use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.